In the present study we investigated, for the first time, if novel siRNNs could enter primary peripheral blood and bone marrow mononuclear cells from pediatric B-ALL patients and induce knockdown of Plk1 mRNA, a key player in the cell cycle and a promising target in cancer therapy. This evidence concerns the gene PLK1 and cancer.